- Home
- ROIV vs CHE Comparison
ROIV vs CHE Comparison
Compare ROIV & CHE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- CHE
- Stock Information
- Founded
- ROIV 2014
- CHE 1970
- Country
- ROIV United Kingdom
- CHE United States
- Employees
- ROIV N/A
- CHE N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- CHE Medical/Nursing Services
- Sector
- ROIV Health Care
- CHE Health Care
- Exchange
- ROIV Nasdaq
- CHE Nasdaq
- Market Cap
- ROIV 7.8B
- CHE 8.0B
- IPO Year
- ROIV N/A
- CHE N/A
- Fundamental
- Price
- ROIV $11.59
- CHE $467.97
- Analyst Decision
- ROIV Buy
- CHE Strong Buy
- Analyst Count
- ROIV 3
- CHE 2
- Target Price
- ROIV $15.25
- CHE $645.00
- AVG Volume (30 Days)
- ROIV 6.5M
- CHE 194.4K
- Earning Date
- ROIV 08-07-2025
- CHE 07-29-2025
- Dividend Yield
- ROIV N/A
- CHE 0.43%
- EPS Growth
- ROIV N/A
- CHE 10.48
- EPS
- ROIV N/A
- CHE 20.53
- Revenue
- ROIV $29,053,000.00
- CHE $2,488,997,000.00
- Revenue This Year
- ROIV $3.28
- CHE $6.20
- Revenue Next Year
- ROIV $156.84
- CHE $6.47
- P/E Ratio
- ROIV N/A
- CHE $22.58
- Revenue Growth
- ROIV N/A
- CHE 8.52
- 52 Week Low
- ROIV $8.73
- CHE $449.01
- 52 Week High
- ROIV $13.06
- CHE $623.61
- Technical
- Relative Strength Index (RSI)
- ROIV 53.30
- CHE 36.29
- Support Level
- ROIV $11.31
- CHE $449.01
- Resistance Level
- ROIV $11.64
- CHE $471.32
- Average True Range (ATR)
- ROIV 0.29
- CHE 9.00
- MACD
- ROIV -0.00
- CHE 3.19
- Stochastic Oscillator
- ROIV 70.23
- CHE 55.53
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About CHE Chemed Corp
Chemed Corp purchases, operates, and divests subsidiaries engaged in diverse business activities to maximize shareholder value. Through its subsidiaries, the company operates in the following segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue and provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers.